ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Genprex Inc

Genprex Inc (GNPX)

0.3576
-0.0178
(-4.74%)
Al cierre: 21 Marzo 2:00PM
0.3503
-0.0073
( -2.04% )
Fuera de horario: 4:21PM

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Último Precio
0.3503
Postura de Compra
0.3503
Postura de Venta
0.36
Volume Operado de la Acción
1,353,059
0.35 Rango del Día 0.37
0.2806 Rango de 52 semanas 4.0899
Capitalización de Mercado [m]
Precio Anterior
0.3754
Precio de Apertura
0.3586
Última hora de negociación
17:32:31
Volumen financiero
US$ 489,390
Precio Promedio Ponderado
0.361692
Volumen promedio (3 m)
1,888,854
Acciones en circulación
8,508,068
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.10
Beneficio por acción (BPA)
-3.63
turnover
-
Beneficio neto
-30.86M

Acerca de Genprex Inc

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who cur... Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
Wilmington, Delaware, USA
Fundado
-
Genprex Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GNPX. The last closing price for Genprex was US$0.38. Over the last year, Genprex shares have traded in a share price range of US$ 0.2806 to US$ 4.0899.

Genprex currently has 8,508,068 shares in issue. The market capitalisation of Genprex is US$3.19 million. Genprex has a price to earnings ratio (PE ratio) of -0.10.

GNPX Últimas noticias

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.0097-2.694444444440.360.520.33118642550.35201677CS
4-0.0452-11.42857142860.39550.520.306234536400.35305259CS
12-0.5547-61.29281767960.9050.92950.306218888540.40986867CS
26-0.0531-13.1631135350.40343.9610.296156971861.96213132CS
52-2.7197-88.58957654723.074.08990.280629246441.92178028CS
156-98.8497-99.64687599.2106.80.280612065018.7927865CS
260-99.6497-99.6497100308.80.2806144166672.84741015CS

GNPX - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Genprex?
El precio actual de las acciones de Genprex es US$ 0.3503
¿Cuántas acciones de Genprex están en circulación?
Genprex tiene 8,508,068 acciones en circulación
¿Cuál es la capitalización de mercado de Genprex?
La capitalización de mercado de Genprex es USD 3.19M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Genprex?
Genprex ha negociado en un rango de US$ 0.2806 a US$ 4.0899 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Genprex?
El ratio precio/beneficio de Genprex es -0.1
¿Cuál es la moneda de reporte de Genprex?
Genprex presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de Genprex?
El último beneficio anual de Genprex es USD -30.86M
¿Cuál es la dirección registrada de Genprex?
La dirección registrada de Genprex es 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Genprex?
La dirección del sitio web de Genprex es www.genprex.com
¿En qué sector industrial opera Genprex?
Genprex opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
IMTEIntergrated Media Technology Ltd
US$ 0.8001
(48.19%)
1.32M
TCBPTC BioPharm Holdings PLC
US$ 0.723
(44.60%)
3.86M
BSGMBioSig Technologies Inc
US$ 0.7428
(36.27%)
125.15k
WINTWindtree Therapeutics Inc
US$ 1.73
(16.89%)
1.18M
RGCRegencell Bioscience Holdings Ltd
US$ 68.20
(16.32%)
60.39k
NVNINVNI Group Ltd
US$ 0.1748
(-28.01%)
3.6M
LGHLLion Group Holding Ltd
US$ 0.0789
(-20.78%)
588.61k
GNLNGreenlane Holdings Inc
US$ 0.3465
(-18.95%)
116.05k
QVCGBQVC Group Inc
US$ 5.50
(-16.92%)
496
SHFSSHF Holdings Inc
US$ 0.2619
(-14.44%)
13.89k
DMNDamon Inc
US$ 0.0377
(1.07%)
19.24M
CSCOCisco Systems Inc
US$ 60.1877
(-0.19%)
8.2M
SGLYSingularity Future Technology Ltd
US$ 1.5407
(-8.29%)
7.43M
YHCLQR House Inc
US$ 0.4568
(14.20%)
6.6M
NVDANVIDIA Corporation
US$ 117.66
(-0.03%)
6.01M

GNPX Discussion

Ver más
Golden Cross Golden Cross 8 horas hace
$GNPX Oversold and Undervalued with a MC of only $3m
👎️ 1 🤢 1
laraz5 laraz5 8 horas hace
Things are so pitiful they are reposting almost 2 year old news?

Rock bottom?

Not even close?

Bankruptcy?

Just wait?


IMO
👍️0
laraz5 laraz5 8 horas hace
Trying to flood social media with hypothetical nonsense?

These 3rd party con job wanna be social media paid hacks invading everywhere with fake adding and dreamed up Genprex ideas?

All while GNPX sells shares?

The very meaning of a pure pump and dump?

Michael Redmond = Ryan Confer?

Are these guys who orchestrated crimes of selling shares based on the idea of Cancer research?

Who does that?


IMO
👍️0
Golden Cross Golden Cross 13 horas hace
Genprex Provides Update on Diabetes Gene Therapy Program

February 18, 2025 Press ReleasesDiabetesgene therapy
Signs an Amended & Restated License Agreement for Multiple Technologies for Gene Therapy for Type 1 and Type 2 Diabetes

Forms a Wholly-Owned Subsidiary, Convergen Biotech, Inc., to Focus Diabetes Program Development

AUSTIN, Texas — (Feb. 18, 2025) —Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: $GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the advancement of its diabetes gene therapy program, including its relationship and collaboration with the University of Pittsburgh of the Commonwealth System of Higher Education (Pitt).

The parties have updated and consolidated the Company’s existing license agreements for technologies from Pitt into a new exclusive license agreement for multiple technologies relating to the development of a gene therapy product for both T1D and T2D. Additionally, the Company has formed a wholly-owned subsidiary, Convergen Biotech, Inc., which will focus on the Company’s diabetes program development.

“We are excited about the advances we are making with our diabetes gene therapy program, including the updated, consolidated exclusive license agreement with the University of Pittsburgh for several technology combinations,” said Ryan Confer, President and Chief Executive Officer at Genprex. “We are also pleased to have formed our wholly-owned subsidiary. In addition, we’re having ongoing discussions with various patient advocacy groups. We believe GPX-002 is a highly innovative, emerging diabetes gene therapy, and we are working to advance this program toward human clinical trials.”

Exclusive License Agreement with the University of Pittsburgh

The new license agreement consolidates the Company’s licensed technologies from Pitt into a single updated agreement which replaces the existing license agreements with Pitt. The amended and restated agreement grants Genprex a worldwide, exclusive license to patent applications and related technologies and a worldwide, non-exclusive license to use certain related know-how, all related to a gene therapy for both T1D and T2D using the genes of the Pdx1 and MafA transcription factors controlled by insulin, glucagon and MafB promoters. This license creates a comprehensive panel of gene therapies exclusively licensed by Genprex for the Company’s diabetes gene therapy program.

“The latest exclusive license agreement synergizes our pre-existing relationship with the University of Pittsburgh, strengthens our intellectual property portfolio for the diabetes gene therapy program and provides Genprex with valuable rights over multiple diabetes gene therapy combinations that we believe have the potential to disrupt the diabetes market,” said Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing. “These technologies are currently being evaluated in preclinical studies at the University of Pittsburgh. As we continue to optimize our construct, we are making strides toward clinical trials.”

The licensed technologies are based on the same general gene therapy approach under Genprex’s original licenses, whereby an adeno-associated virus vector containing the Pdx1 and MafA genes is administered directly into the pancreatic duct. In humans, this can be done with a routine endoscopy procedure. GPX-002 is being developed using the same construct for the treatment of both T1D and T2D. In T1D, GPX-002 is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-002 for T2D, where autoimmunity is not a factor, is believed to rejuvenate and replenish exhausted beta cells.

Each of these technologies may have the potential to provide long-term efficacy, potentially changing the course of this disease for the millions of patients around the world with diabetes. All of the diabetes technologies licensed from Pitt by Genprex were developed in the laboratory of George Gittes, MD, Professor of Surgery and Pediatrics and Chief of the Division of Pediatric Surgery at the University of Pittsburgh School of Medicine.

The Company has finalized components of the diabetes construct and is continuing with its planned preclinical studies. Genprex plans to request FDA’s guidance for the preclinical studies needed to file an Investigational New Drug (IND) application and initiate first-in-human studies and is poised for FDA Guidance on IND-enabling diabetes studies by the second half of 2025.

Formation of a Wholly-Owned Subsidiary

In addition, as announced in September 2024, Genprex believes separating its diabetes program from its oncology program into a new, wholly-owned subsidiary could expedite clinical development and enable potential direct investment and strategic collaboration into its diabetes program. In connection with the intended separation of its diabetes clinical development program, Genprex has formed a wholly-owned subsidiary, Convergen Biotech, Inc. Genprex believes implementing this initial step and facilitating the separation of its diabetes program into Convergen Biotech will allow both Genprex and Convergen Biotech to enhance each program’s focus on meeting the needs of their respective markets and patients. The decision to implement this initial step of the reorganization demonstrates Genprex’s strong ongoing commitment to the Company’s streamlined, focused strategies and prioritization of its ongoing research and development prioritization initiative.

About Diabetes

According to the U.S. Center for Disease Control as of 2024, 38.4 million Americans, or approximately 11.6% of the U.S. population, have diabetes. Approximately 10% of this total has T1D and approximately 90-95% of this total has T2D. It is also believed that more than 97 million Americans aged 18 years or older have prediabetes. In 2021, approximately 537 million adults (20-79 years) worldwide were living with diabetes, and the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million in 2045. Approximately 7.7 million adults over the age of 20 live with T1D worldwide, and approximately 1.6 million children and adolescents under the age of 20 live with T1D worldwide. Also in 2021, diabetes caused more than 6.7 million deaths globally and diabetes resulted in approximately $966 billion dollars in health expenditures, a 316% increase over the preceding fifteen years.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company’s lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex’s lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex’s SCLC program has received an FDA Orphan Drug Designation. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
👍️ 1 👎️ 1 💯 1 🤑 1 🤢 1
Golden Cross Golden Cross 13 horas hace
Company’s CEO and CFO Highlights its Cutting-Edge Gene Therapy Programs

AUSTIN, Texas — (Sept. 23, 2024) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: $GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company’s President, Chief Executive Officer and Chief Financial Officer, Ryan Confer, was featured in CEO/CFO Magazine discussing the Company’s novel gene therapies for cancer and diabetes.

In this article, Confer describes the Company’s gene therapy approaches in oncology and diabetes, recent updates to the Company’s Acclaim clinical trials in lung cancer, and the Company’s new use of biomarker testing for its oncology program. In diabetes, Confer comments on the popularity of GLP-1 agonists such as Novo Nordisk’s Ozempic® and other new diabetic treatments, the future of potential partnerships and collaborations in gene therapy and for Genprex, and the medical and investment community’s understanding of the potential value of gene therapy for diabetes.

Confer states in the CEO Magazine article:

“One thing we are excited about – as we just recently announced – is our plan to launch a spin out of our diabetes program into a wholly-owned subsidiary of Genprex. We believe this will allow us to explore potential partnerships with those entities solely focused on the diabetes program and find the right funding, partners, and collaborators that could drive these programs forward, which is important to us in terms of getting these innovative drugs to patients faster and to creating value for our stakeholders.”

To read the article in its entirety, please visit the Media Coverage section on Genprex’s website.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company’s lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex’s lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex’s SCLC program has received an FDA Orphan Drug Designation. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
👍️0
georgie18 georgie18 1 día hace
GNPX...out for a wash...🥳
👍️0
laraz5 laraz5 1 día hace
How come non of the 3rd party promoters will answer the current O/S of Genprex?

Can they?

Maybe they have a conscience where they can't lie only misleadi?

IMO
👍️0
Golden Cross Golden Cross 1 día hace
Coming off days lows nice here .40's in sight...
👍️0
Golden Cross Golden Cross 1 día hace
$GNPX Swinging for .50+...On News Watch Here! Conference finished yesterday and now think we see news real soon...Loading!!!
👍️0
laraz5 laraz5 1 día hace
No more fake adding today? 3rd party promoters?

Taking the day off while the company offs another few million shares?

What's the O/S currently GNPX?

Surely people aren't adding based upon a company not reporting since last year?

Could be?

Ryan M Confer could be orchestrating one of the biggest con jobs in medical history?

Is Ryan M Confer CEO of Genprex stealing Investors money?


Is Ryan M Confer selling shares based off the sentiment of Cancer?

That would be the lowest form of life if anything Individual would do that?

IMO
👍️0
laraz5 laraz5 2 días hace
The fake adding by 3rd party con artist promoters is laughable platered all over social media?

Typical cons over on X screaming about how they keeping adding over and over and over again?

I wonder if they sold the 1.40s they bought a few weeks back?

As GNPX keep selling they keep buying?

Lower and lower?

Shameful fake adding?

Gross?

IMO
👍️0
Golden Cross Golden Cross 2 días hace
$GNPX Adding here...Chart is reversing...
👍️0
georgie18 georgie18 2 días hace
GNPX....3825...NHOD...🥳

georgie18

Member Level
Re: georgie18 post# 677254

Wednesday, March 19, 2025 10:26:41 AM

Post#
677268
of 677322
GNPX....37...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 4054

Wednesday, March 19, 2025 10:04:27 AM

Post#
4056
of 4056
GNPX...3564...🥳...Trying to Reverse here...

georgie18

Member Level
Re: georgie18 post# 677148

Tuesday, March 18, 2025 7:41:03 PM

Post#
677236
of 677253
GNPX...Added some .33s...🥳

georgie18

Member Level
Re: None

Tuesday, March 18, 2025 10:55:31 AM

Post#
4052
of 4053
GNPX...42...Filled some here...🥳
👍️0
georgie18 georgie18 2 días hace
GNPX....37...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 4054

Wednesday, March 19, 2025 10:04:27 AM

Post#
4056
of 4056
GNPX...3564...🥳...Trying to Reverse here...

georgie18

Member Level
Re: georgie18 post# 677148

Tuesday, March 18, 2025 7:41:03 PM

Post#
677236
of 677253
GNPX...Added some .33s...🥳

georgie18

Member Level
Re: None

Tuesday, March 18, 2025 10:55:31 AM

Post#
4052
of 4053
GNPX...42...Filled some here...🥳
👍️0
georgie18 georgie18 2 días hace
GNPX...3564...🥳...Trying to Reverse here...

georgie18

Member Level
Re: georgie18 post# 677148

Tuesday, March 18, 2025 7:41:03 PM

Post#
677236
of 677253
GNPX...Added some .33s...🥳

georgie18

Member Level
Re: None

Tuesday, March 18, 2025 10:55:31 AM

Post#
4052
of 4053
GNPX...42...Filled some here...🥳
👍️0
laraz5 laraz5 3 días hace
Complete horseshit no you didn't?


IMO
👍️0
georgie18 georgie18 3 días hace
GNPX...Added some .33s...🥳

georgie18

Member Level
Re: None

Tuesday, March 18, 2025 10:55:31 AM

Post#
4052
of 4053
GNPX...42...Filled some here...🥳
👍️0
laraz5 laraz5 3 días hace
Ryan M Confer should be in jail if he is taking part in a pump and dump medical scheme diluting mass shares and not reporting the numbers?

How come Genorex does not report current O/S?

What are they hiding?

Is the O/S still 8 million?

Ryan M Confer CEO of Genprex are you there?

IMO
👍️0
georgie18 georgie18 3 días hace
GNPX...42...Filled some here...🥳
👍️0
81vette 81vette 3 días hace
Zero borrow
👍️0
laraz5 laraz5 4 días hace
What's the O/S currently? If you're going to promote absolute trash scams please come with updated info?


IMO
👍️0
glenn1919 glenn1919 4 días hace
gnpx.................................https://stockcharts.com/h-sc/ui?s=gnpx&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 3 semanas hace
Ate up .38s dilution heaven 
👍️0
tw0122 tw0122 1 mes hace
Love heavily diluted garbage Pharma plays picked up some .43s this round stop loss .41. Could it go back to .20s maybe will catch and reassess but been steady .40s for another possible dilution flip. 
👍️0
laraz5 laraz5 1 mes hace
Stop selling lies? GNPX took a shelved product, tweaked it and is now selling millions of shares based upon it?

It's the same gang over and over diluting shells?

You're literally down 20% since yesterday horrific .55 call?

Just like the calls at 3 dollars 2 dollars 1 dollar?

Imagine people actually listened?

All the the inner workings of this pyramid scheme need jail time?

Payne is dead?
Redmond moved on?
Confer is a nervous wreck?

IMO

IMO
👍️0
laraz5 laraz5 1 mes hace
Oh the con artist 3rd party promo gang storming the interwebs claiming they keep buying?

Which is the same claims they have been making from 3 dollars to 40 cents?

Same adding at every level?

Same losing at every level?

All while they can't even tell you what the O/S has ballooned to because GNPX refuses to update it?

Dilution?

Scam?

Going to sub penny?


But no worries they will offer another reverse split soon?

Pump and dump pyramid scheme?

IMO
👍️0
weedtrader420 weedtrader420 1 mes hace
☝️🤑☝️
👍️0
georgie18 georgie18 1 mes hace
Yup in there and been adding to average down...🥳Thanks didnt notice today's news...
👍️0
tw0122 tw0122 1 mes hace
GNPX.53 +11% 8m floater results lung cancer good... A significant antitumor effect was also found in non-humanized NSG mice, although the antitumor effect was greater in humanized mice, suggesting that the effects of NPRL2 gene therapy are achieved through the immune system. This is consistent with a more detailed analysis showing that NPRL2 gene therapy induces antitumor activity against KRAS/STK11 mutant anti-PD1 resistant tumors through dendritic cell mediated antigen presentation and cytotoxic immune cell activation. KRAS/STK11 mutant tumors are particularly resistant to treatment, and demonstrating efficacy in this setting suggests that a wide variety of lung cancers could potentially be targeted. This potentially would include the approximately 30% of NSCLCs that have KRAS mutations.
👍️0
laraz5 laraz5 2 meses hace
What a horrible trade? You've done nothing but post buys lower and lower?

Feeding right into the dilution?

While claiming some false DD led you to Invest?

How could anyone be this wrong every time?

IMO
👍️0
laraz5 laraz5 2 meses hace
Seems they haven't reported the O/S since November?

Any guesses why?

I have an idea?

Theft?

IMO
👍️0
laraz5 laraz5 2 meses hace
These con artist promoters are now updating there calls lower lower and lower?

Always adding?

PPS always dropping?

They mist be shorting?

GNPX could be a pyramid scheme using the sympathetic nature of Cancer as a way to dilute and steal funds from innocent investors?

IMO
👍️0
laraz5 laraz5 2 meses hace
You are down already? You've called this from 2.00 to .71 adding all the way?

You might want to DD because at this rate it appears your are just losing money and giving out bad advice?

IMO
👍️0
georgie18 georgie18 2 meses hace
GNPX...76...Added on News...🥳...https://www.prnewswire.com/news-releases/genprex-announces-first-patient-dosed-in-phase-2-expansion-portion-of-acclaim-3-clinical-study-of-reqorsa-gene-therapy-in-combination-with-tecentriq-to-treat-small-cell-lung-cancer-302358445.html

georgie18

Member Level
Re: georgie18 post# 4032

Monday, December 16, 2024 9:31:30 AM

Post#
4034
of 4037
GNPX...$1.26...🥳...AUSTIN, Texas , Dec. 16, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has completed the Phase 1 dose escalation portion of the Acclaim-3 clinical trial of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with Tecentriq® (atezolizumab) as maintenance therapy to treat patients with extensive stage small cell lung cancer (ES-SCLC). In addition, the Safety Review Committee (SRC) has approved the opening of the Phase 2 expansion portion of the trial.

The combination of REQORSA and atezolizumab previously received U.S. Food and Drug Administration's (FDA) Fast Track Designation for the treatment of the Acclaim-3 patient population, and the FDA has also granted Orphan Drug Designation to REQORSA for the treatment of SCLC.

Based on full safety data, which showed no dose limiting toxicities (DLTs), the SRC determined that the Recommended Phase 2 Dose (RP2D) of REQORSA will be 0.12 mg/kg. This was the highest dose level delivered in the Phase 1 portion of the trial. The SRC also recommended the trial advance to the Phase 2 expansion portion of the study, which the Company has now opened for enrollment.
👍️0
laraz5 laraz5 2 meses hace
Good Job fraud promoters coming in and plastering crap about this pyramid scheme at 1.5 now almost down 50% in just about a month?

Well done?

How many got diluted?

Tough to say since GNPX doesn't report?

Loophole?

Nothing like a scam off the backs of Cancer?

Ryan Confer might be knowing frauding the public off the idea of Cancer?

What kind of low life does such a thing?

Rodney Varner the man with many names and many years of stick manipulation does suddenly and Ryan Confer takes over?

How deep does the pyramid scheme of GNPX go?

IMO
👍️0
laraz5 laraz5 3 meses hace
Unlimited theft in the name of Cancer research?

It's one thing to create an imaginary product and sell shares of its ideas?

But to sell shares based on the idea of combating cancer takes some sick people?

IMO
👍️0
georgie18 georgie18 3 meses hace
GNPX...$1.26...🥳...AUSTIN, Texas , Dec. 16, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has completed the Phase 1 dose escalation portion of the Acclaim-3 clinical trial of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with Tecentriq® (atezolizumab) as maintenance therapy to treat patients with extensive stage small cell lung cancer (ES-SCLC). In addition, the Safety Review Committee (SRC) has approved the opening of the Phase 2 expansion portion of the trial.

The combination of REQORSA and atezolizumab previously received U.S. Food and Drug Administration's (FDA) Fast Track Designation for the treatment of the Acclaim-3 patient population, and the FDA has also granted Orphan Drug Designation to REQORSA for the treatment of SCLC.

Based on full safety data, which showed no dose limiting toxicities (DLTs), the SRC determined that the Recommended Phase 2 Dose (RP2D) of REQORSA will be 0.12 mg/kg. This was the highest dose level delivered in the Phase 1 portion of the trial. The SRC also recommended the trial advance to the Phase 2 expansion portion of the study, which the Company has now opened for enrollment.
👍️0
BurgerKing82 BurgerKing82 3 meses hace
Looking good...P.T?
👍️0
georgie18 georgie18 3 meses hace
GNPX...$1.12...🥳...Psar flipped Bullish...Bollies are starting to Squeeze here...Been averaging down and Accumulating...
👍️0
laraz5 laraz5 4 meses hace
New O/S 8,508,068 six million shares diluted since last report month back?

6 million shares while the con artist 3rd party promoters came in and played pump n dump with the shell?

Don't anyone worry the O/S is going much higher and the PPS is going much lower?

Does Ryan M Confer understand about pyramid schemes?

I believe Rodney Varner is going to have some explaining to do where he is headed?

If Ryan M Confer turned out to take the torch from Varner by getting cancer products tweaking them and diluting shares while creating a false hope then this won't be his last time getting involved in possible pyramid schemes?

IMO

👍️0
laraz5 laraz5 4 meses hace
You think you know the current O/S or will you guess at that as well?

GNPX is a pyramid scheme?

IMO
👍️0
Savannah-Marc Savannah-Marc 4 meses hace
I think it will run but "when" is the question, depends on if we get a favorable settlement or judgement from the court case. I think the appellant is running the clock to come up with a decent enough settlement agreement because in my opinion, a court decision would ruin them.
👍️0
J2003 J2003 4 meses hace
More news tomorrow!
👍️0
laraz5 laraz5 4 meses hace
What's the current O/S? Since shamelessly promoting a pyramid scheme tanking daily off news at least tell shareholders what's the current O/S is?

Unless you simply don't know it?

Stop promoting scams?

IMO
👍️0
georgie18 georgie18 4 meses hace
GNPX...$1.27...NEWS...🥳...https://www.prnewswire.com/news-releases/genprex-signs-exclusive-license-to-additional-gene-therapy-technologies-with-the-university-of-michigan-for-the-treatment-of-lung-cancer-302311506.html
👍️0
laraz5 laraz5 4 meses hace
Scoop like cat litter? Does Ryan know where this possible pyramid scheme was originated and how this ends for him?

Does Ryan Confer just get to walk away after a possible billions are diluted and GNPX tumbles into BK?

Michael T Redmands stank is still riddled in this mess?

IMO
👍️0
CelestialEnchanter69 CelestialEnchanter69 4 meses hace
Get the Inside Scoop on Genprex
Want to know more about Genprex (NASDAQ: GNPX)? Watch the exclusive interview with CEO Ryan Confer. He discusses the company's latest developments in diabetes and oncology.
Join the Future 1% community for free to access this insightful interview and other exclusive content.

https://marathonmoneyplus.com/2024/10/28/marathon-money-ft-ceo-mr-ryan-m-confer-m-s-genprex-gnpx/

#MarathonMoney #Future1% #GNXP #biotech #investing
👍️0
laraz5 laraz5 4 meses hace
GNPX is failing to disclose the O/S?

Is it still 2.5 million?

Or 50,000?

They seem to have neglected any reporting since August?

Seems like a Michael Redmond type of pyramid scheme?

Oh don't worry they fired him after he drew them a blueprint?


Bankruptcy soon but no jail time they all get away with it?


IMO
👍️0
laraz5 laraz5 4 meses hace
2.09? Hahaha loser 3rd party promoters trying to sell crap? It reduced tumors?

Does anyone believe such garbage?

These animals come around screaming about falsehoods while they sell?

GNPX could very well be a pyramid scheme selling millions and millions of shares while low intelligence 3rd party cons come in and drop lies?

Already down another 10%?

Keep them newsletters coming con artists?

Don't believe me then tell me what the O/S is today?

IMO
👍️0
tw0122 tw0122 4 meses hace
Reduced tumors in mice, regained compliance,
Low floater $2.09.
GNS nice flip last night 
👍️0